Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4427 Target Snapshot

Prostaglandin D2 receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,022Compounds
131Assays
9Approved Drugs
1,176.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Prostaglandin D2 receptor shows late clinical disease relevance led by Combined hyperlipidemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13258. Start with Combined hyperlipidemia, then reuse UniProt Q13258 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Combined hyperlipidemia, then reuse UniProt Q13258 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Combined hyperlipidemia

Prostaglandin D2 receptor shows late clinical disease relevance led by Combined hyperlipidemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Combined hyperlipidemia because it currently carries late clinical support. Linked drugs include LAROPIPRANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin D2 receptor as ChEMBL target CHEMBL4427, mapped to UniProt Q13258. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin D2 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4427
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13258
Prostaglandin D2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Prostaglandin D2 receptor is the right protein anchor across sources, using UniProt Q13258 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Combined hyperlipidemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProstaglandin D2 receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ13258
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProstaglandin D2 receptor
UniProt AccessionQ13258
Component TypeProtein
Sequence Length359 aa

Prostaglandin D2 receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Prostaglandin D2 receptor, mapped to UniProt Q13258. Sequence length is 359 aa.

Mapped IDQ13258
Review nameProstaglandin D2 receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Prostaglandin D2 receptor shows late clinical disease relevance led by Combined hyperlipidemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
Combined hyperlipidemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Late clinical Phase III
Disorder of lipid metabolism
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Late clinical Phase III
familial hypercholesterolemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Late clinical Phase III
Hypercholesterolemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Late clinical Phase III
hyperlipidemia
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Late clinical Phase III
type 2 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugLAROPIPRANT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Combined hyperlipidemia because it currently carries late clinical support. Linked drugs include LAROPIPRANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCombined hyperlipidemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
6
Phase III
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50647.0
KI343.0
EC50185.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1644207 10.7 IC50 0.01995 Preclinical
CHEMBL426559 10.52 Kd 0.03 Approved
CHEMBL1644214 10.3 IC50 0.05012 Preclinical
CHEMBL426559 10.05 IC50 0.09 Approved
CHEMBL1644206 10.0 IC50 0.1 Preclinical
CHEMBL483991 9.85 IC50 0.14 Preclinical
CHEMBL484778 9.66 IC50 0.22 Preclinical
CHEMBL426387 9.59 IC50 0.26 Preclinical
CHEMBL116836 9.57 IC50 0.27 Preclinical
CHEMBL385126 9.54 IC50 0.29 Preclinical
Distribution

pChEMBL Value Distribution

81
5.0
114
5.5
131
6.0
120
6.5
87
7.0
99
7.5
73
8.0
52
8.5
45
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

SELEXIPAG
CHEMBL238804
Approved 2015
Properties Compare Identifier
ILOPROST
CHEMBL494
Approved 2003
Properties Compare Identifier
TREPROSTINIL
CHEMBL1237119
Approved 2002
Properties Compare Identifier
LAROPIPRANT
CHEMBL426559
Properties Compare Identifier
Assay Landscape

Assay Landscape

131
Total Assays
448
Tested Compounds
2
Assay Types
Binding — 91 assays, 448 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 51 113 6.8
cell-based format 32 152 7.3
assay format 4 114 6.8
cell membrane format 4 69 5.5
Functional — 40 assays, 313 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 17 107 7.4
assay format 16 196 6.8
cell-free format 3 7 8.1
single protein format 2 3 6.4
tissue-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine